文献速递脊柱关节炎其他结缔组织病

银屑病患者银屑病关节炎筛查的成本效果模型

Model to Determine the Cost-Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

该研究在加拿大构建Markov模型,评估四种筛查问卷在银屑病患者中筛查银屑病关节炎的成本效果。结果显示筛查相比不筛查具有成本效果,EARP问卷总成本最低且QALY最高,结果对检测准确性和DMARD疗效最敏感。

要点

  • 筛查银屑病患者中的PsA相比不筛查具有成本效果。
  • EARP问卷总成本最低(每人每年节省2000加元)且QALY增益最高(每患者增加0.18)。
  • 若DMARD不能延缓疾病进展,则不筛查在每QALY 50000加元阈值下具有成本效果。

研究设计与样本

  • 研究构建Markov模型,估算在加拿大银屑病患者中使用筛查工具筛查PsA的成本和质量调整生命年(QALY)。
  • 筛查工具包括Toronto Psoriatic Arthritis Screen、Psoriasis Epidemiology Screening Tool、Psoriatic Arthritis Screening and Evaluation和Early Psoriatic Arthritis Screening Questionnaire(EARP)问卷。
  • 健康状态由Health Assessment Questionnaire测量的残疾水平定义,状态转移基于年度疾病进展建模。
  • 估计增量成本效果比和增量净货币效益,并进行敏感性分析以考虑参数不确定性和检验模型假设。

主要发现

  • 筛查相比不筛查具有成本效果。
  • EARP工具总成本最低,相比不筛查每人每年节省2000加元。
  • EARP工具总QALY最高,相比不筛查每患者增加0.18。
  • 结果对检测准确性和改善病情抗风湿药(DMARD)的疗效最敏感。

关键数值与推荐

  • EARP问卷相比不筛查每人每年节省2000加元。
  • EARP问卷相比不筛查每患者增加0.18 QALY。
  • 当DMARD不能延缓疾病进展时,在每QALY 50000加元阈值下不筛查相比筛查具有成本效果。

临床怎么用

  • 在加拿大银屑病患者中实施PsA筛查可能节省成本并改善生活质量,前提是早期DMARD治疗能延迟生物制剂使用。
  • EARP问卷在模型中表现最优,但筛查的成本效果高度依赖于检测准确性和DMARD延缓疾病进展的疗效。

局限性

  • 结果基于模型假设,对检测准确性和DMARD疗效敏感;若DMARD不能延缓疾病进展,筛查则不再具有成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Screening psoriasis patients for psoriatic arthritis (PsA) is intended to identify patients at earlier stages of the disease. Early treatment is expected to slow disease progression and delay the need for biologic therapy. Our objective was to determine the cost-effectiveness of screening for PsA in patients with psoriasis in Canada. METHODS: A Markov model was built to estimate the costs and quality-adjusted life years (QALYs) of screening tools for PsA in psoriasis patients. The screening tools included the Toronto Psoriatic Arthritis Screen, Psoriasis Epidemiology Screening Tool, Psoriatic Arthritis Screening and Evaluation, and Early Psoriatic Arthritis Screening Questionnaire (EARP) questionnaires. States of health were defined by disability levels as measured by the Health Assessment Questionnaire. State transitions were modeled based on annual disease progression. Incremental cost-effectiveness ratios and incremental net monetary benefits were estimated. Sensitivity analyses were undertaken to account for parameter uncertainty and to test model assumptions. RESULTS: Screening was cost-effective compared to no screening. The EARP tool had the lowest total cost ($2,000 per patient per year saved compared to no screening) and the highest total QALYs (additional 0.18 per patient compared to no screening). The results were most sensitive to test accuracy and the efficacy of disease-modifying antirheumatic drugs (DMARDs). No screening was cost-effective (at $50,000 per QALY) relative to screening when DMARDs failed to slow disease progression. CONCLUSION: If early therapy with DMARDs delays biologic treatment, implementing screening in patients with psoriasis in Canada is expected to represent a cost savings of $220 million per year and improve the quality of life.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Iragorri N, Hazlewood G, Manns B, et al. Model to Determine the Cost-Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2021. PMID: 31733035. doi:10.1002/acr.24110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。